Ondine Biomedical Inc. Appointment of new Chief Financial Officer (8435Z)
16 Gennaio 2024 - 9:15AM
UK Regulatory
TIDMOBI
RNS Number : 8435Z
Ondine Biomedical Inc.
16 January 2024
16 January 2024
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")
Appointment of new Chief Financial Officer
Canadian life sciences company Ondine Biomedical Inc. (LON: OBI)
has appointed Joseph P. ("JP") Errico as Chief Financial
Officer.[i] JP will be responsible for managing and developing
Ondine's finance function, as well as managing the capital markets
interface, participating in discussions with large health systems
and customers, and working closely with the management team on
overall growth strategy, both from a financial and operational
perspective.
JP has successfully founded and sold (or taken public) several
medical device and pharmaceutical companies, including ElectroCore,
Fastenetix, K2 Medical Systems, AD4-Pharma, E2, and SpineCore, with
his patented products generating over $20 billion in sales.
Carolyn Cross, CEO and founder of Ondine commented:
"We are delighted that JP has agreed to join Ondine at this
exciting time. His experience in finance, capital markets and
developing medtech companies will be invaluable as we move forward
with our international expansion and achieving FDA approval in
conjunction with our partner HCA Healthcare."
JP Errico commented:
"Ondine represents a unique opportunity to create shareholder
value while heading off one of humanity's greatest health threats,
antimicrobial resistance. I am proud to be joining an excellent
team of professionals as Ondine brings this critically needed
technology to the world."
JP's educational background includes an undergraduate degree in
Aeronautical Engineering from the Massachusetts Institute of
Technology and graduate degrees in both Law and
Mechanical/Materials Engineering from Duke University. He is also a
trained patent attorney.
*ENDS*
Enquiries:
Ondine Biomedical Inc.
+001 (604) 838
Angelika Vance, Corporate Communications 2702
Singer Capital Markets (Nominated Adviser
and Joint Broker)
+44 (0)20 7496
Aubrey Powell, Asha Chotai, Sam Butcher 3000
RBC Capital Markets (Joint Broker)
+44 (0)20 7653
Rupert Walford, Kathryn Deegan 4000
Vane Percy & Roberts (Media Contact)
+44 (0)77 1000
Simon Vane Percy, Amanda Bernard 5910
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life science company
innovating in the field of photodisinfection therapies. Ondine has
a pipeline of investigational products, based on its proprietary
photodisinfection platform, in various stages of development.
Ondine's nasal photodisinfection technology is approved in several
jurisdictions under the brand name Steriwave(R). It has been
awarded the CE mark and, in the US, has been granted Qualified
Infectious Disease Product designation and Fast Track status by the
FDA. Products beyond nasal photodisinfection include therapies for
a variety of medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns, and other indications.
[i] A non-board position.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAEAPFKFENLEEA
(END) Dow Jones Newswires
January 16, 2024 03:15 ET (08:15 GMT)
Grafico Azioni Ondine Biomedical (LSE:OBI)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Ondine Biomedical (LSE:OBI)
Storico
Da Set 2023 a Set 2024